March 26 (Reuters) - Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection.
The company said the drug, Arikayce, did not reduce bacterial density, a measure of change in infection, in patients with nontuberculous mycobacterial lung infections.
The trial compared the drug, in combination with a standard treatment, to a combination of placebo and the standard treatment.
(Reporting By Vrinda Manocha in Bangalore; Editing by Savio D'Souza)
- Health Care Industry
- Pharmaceuticals & Drug Trials
- experimental drug